Press Releases

Year

Apr 16, 2019

Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference Phase 2/3 clinical trial for suvodirsen in DMD expected to initiate in July 2019 Interim efficacy data from ongoing open-label extension study expected in H2 2019 Investor conference call scheduled

Apr 12, 2019

Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference

Suvodirsen Phase 1 Safety and Tolerability Results Accepted for Oral Presentation Investor Conference Call and Webcast Scheduled for Tuesday, April 16 CAMBRIDGE, Mass. , April 12, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to

Apr 10, 2019

Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs

Topline data readout from Huntington’s disease clinical trials now expected by year end 2019 CAMBRIDGE, Mass. , April 10, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling

Mar 25, 2019

Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference

CAMBRIDGE, Mass. , March 25, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that four poster presentations highlighting new data and

Mar 06, 2019

Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference

CAMBRIDGE, Mass. , March 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

Mar 01, 2019

Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update

Outlines plans for building a fully integrated genetic medicines company CAMBRIDGE, Mass. , March 01, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases,

Jan 24, 2019

Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares

CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten

Jan 23, 2019

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

CAMBRIDGE, Mass. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of

Jan 03, 2019

Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program

Suvodirsen (WVE-210201) Phase 2/3 trial chosen in inaugural round of pilot program FDA pilot program is a 21 st Century Cures Act initiative CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational